KRAS G12C is the hot new play in can­cer R&D, and No­var­tis jumps in with a com­bo deal

These days in the fren­zied can­cer R&D field, every step for­ward with a monother­a­py is al­most im­me­di­ate­ly fol­lowed by a com­bo ap­proach. And we’re see­ing that again to­day.

A lit­tle more than a month since Am­gen whipped up some ex­cite­ment for its KRAS G12C pro­gram with a pos­i­tive ear­ly snap­shot of hu­man da­ta at AS­CO, No­var­tis is step­ping in­to the are­na — adding a part­ner­ship that puts them in the race with a com­bi­na­tion that will like­ly get plen­ty of added at­ten­tion in the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER